Adcendo ApS is a Copenhagen-based biotech company focused on developing first-in-class antibody-drug conjugates (ADCs) specifically designed to treat cancers with significant unmet medical needs. Their innovative approach combines a deep understanding of novel targets with optimized ADC technology, allowing for the targeted delivery of highly cytotoxic drugs to malignant cells that overexpress specific surface antigens. This targeted mechanism enhances the efficacy of cancer treatments while minimizing damage to healthy tissues, making ADCs a promising modality in oncology.

The company's pipeline includes several ADC programs, such as ADCE-T02, ADCE-D01, ADCE-B05, and A0401, which are currently advancing through clinical development. Adcendo's recent $135 million Series B financing round will support the progression of these programs, aiming to achieve clinical proof of concept. The company is committed to addressing the challenges of treating hard-to-treat cancers and is positioned to be a leader in the next era of ADC drug development, with the potential to significantly alter treatment paradigms for various cancer types.

Denmark

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. 

In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. 

Read more at www.adcendo.com

Adcendo

Company Details